What's Happening?
VahatiCor, a medtech company focused on cardiac care, has secured $23 million in Series B funding. The investment was led by S3 Ventures, with additional support from Intuitive Ventures and a strategic investor. The funds will be used to advance VahatiCor's
SERRA-I early feasibility study, which involves 30 subjects across six sites, accelerate engineering development, and prepare for pivotal trials. Coronary Microvascular Dysfunction (CMD) affects an estimated 3-4 million Americans, causing chest pain and angina without blockages in major coronary arteries. CMD is particularly concerning for women, who face a higher risk of cardiac events due to impaired coronary flow. VahatiCor's A-FLUX Reducer System® aims to address this issue by optimizing and redistributing oxygenated blood flow through a coronary sinus reducer device.
Why It's Important?
The funding and development of VahatiCor's A-FLUX Reducer System® are significant as CMD remains a critical public health issue with limited treatment options. Existing medications fail over half of CMD patients, and no current treatments directly improve coronary blood flow. The device's innovative design offers procedural safety and efficacy, potentially providing a new therapeutic option for patients with limited choices. This advancement could lead to improved cardiac care and outcomes, particularly for women who are disproportionately affected by CMD. The success of VahatiCor's trials and device development could pave the way for broader adoption and integration into cardiac care practices.
